171 results on '"Tota, Joseph E."'
Search Results
2. Efficacy of the AS04-adjuvanted HPV-16/18 vaccine: Pooled analysis of the Costa Rica Vaccine and PATRICIA randomized controlled trials
3. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
4. Impact of a carrageenan gel on viral load of genital human papillomavirus infections in sexually active women: Findings from the Carrageenan‐gel Against Transmission of Cervical Human papillomavirus (CATCH) trial
5. Use of a carrageenan‐based gel had no impact on anal HPVs 16 and 18 viral loads in gay, bisexual, and other men who have sex with men
6. Design and methods for the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial
7. Inflammatory Tongue Conditions and Risk of Oral Tongue Cancer Among the US Elderly Individuals.
8. High Risk of New HPV Infection Acquisition Among Unvaccinated Young Men
9. High Risk of New HPV Infection Acquisition Among Unvaccinated Young Men.
10. Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening
11. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm
12. Rising incidence of oral tongue cancer among white men and women in the United States, 1973–2012
13. Trends in cervical cancer incidence in younger US women from 2000 to 2013
14. Self-applied carrageenan-based gel to prevent human papillomavirus infection in sexually active young women: Final analysis of efficacy and safety of a randomised controlled trial
15. Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019:Population impact of multi‐cohort vaccination against human papillomavirus infection
16. Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections
17. Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019: Population impact of multi‐cohort vaccination against human papillomavirus infection
18. Younger age distribution of cervical cancer incidence among survivors of pediatric and young adult cancers
19. The accuracy of human papillomavirus vaccination status based on adult proxy recall or household immunization records for adolescent females in the United States: results from the National Immunization Survey-Teen
20. Incidence of cervical precancerous lesions and cervical cancer in Denmark from 2000 to 2019: Population impact of multi‐cohort vaccination against human papillomavirus infection.
21. Human Papillomavirus Infection and Bladder Cancer: An Alternate Perspective From a Modified Meta-Analysis
22. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies
23. Lung Cancer Screening: Review and Performance Comparison Under Different Risk Scenarios
24. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs
25. Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial
26. Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial
27. Progress on human papillomavirus (HPV) infection and cervical cancer prevention in sub-Saharan Africa: Highlights of the 27th International Papillomavirus Conference in Berlin, 17–22 September 2011
28. Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States
29. Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial.
30. Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination
31. Cervical human papillomavirus detection is not affected by menstrual phase
32. Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine Trial.
33. Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study
34. Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening
35. Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study.
36. Development and validation of an individualized risk prediction model for oropharynx cancer in the US population
37. Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals
38. Journal editors as curators of scholarship: A case study in repairing the scientific record
39. Risk of oral tongue cancer among immunocompromised transplant recipients and human immunodeficiency virus-infected individuals in the United States
40. Population health intervention research: A renewed commitment to promoting a science of solutions
41. Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination
42. Should we lower the age for routine HPV vaccination in the United States?
43. An elusive low-hanging fruit for public health: Gun violence prevention
44. Sobering realizations in cancer prevention and screening and their lessons
45. CERVICAL CANCER SCREENING RECOMMENDATIONS FOR CANADA: CREDIBLE, VALID, AND NOT CONFLICTED.
46. Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials.
47. Evaluation of Human Papillomavirus Type Replacement Postvaccination Must Account for Diagnostic Artifacts: Masking of HPV52 by HPV16 in Anogenital Specimens
48. Striving for excellence while adapting to change: Redefining our mission of serving the preventive medicine community
49. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs
50. Inequalities in vaccination coverage for young females whose parents are informal caregivers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.